Concepedia

Author

John Catalano

Frankston Hospital

Also Known As

J. V. Catalano, John Catalano, John F. DiPersio, John V Catalano, John V. Catalano, John Vincent Catalano, for the RESUME trialists

103

Publications

10.5K

Citations

37

H-Index

60

Concepts

All Affiliations

Frankston HospitalMonash UniversityPrincess Margaret Cancer CentreMayo Clinic in ArizonaEmory University
JC

About

John Catalano is an author at Frankston Hospital specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

13

2.5K

2

Health Sciences

5

5

756

3

Public Health

3

3

139

4

Law

1

1

31

5

Social Sciences

1

1

31

John Catalano

×

58

Publications

10K

Citations

36

H-Index

YearCitations

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib,

New England Journal of Medicine

2012

2K

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles, John F. Seymour, Fritz Offner,

The Lancet

2010

1.1K

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri,

New England Journal of Medicine

2014

780

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Antonio Palumbo, Roman Hájek, Michel Delforge,

New England Journal of Medicine

2012

737

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

Robert Marcus, Kevin Imrie, Philippe Solal‐Céligny,

Journal of Clinical Oncology

2008

590

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

Tadeusz Robak, Anna Dmoszyńska, Philippe Solal‐Céligny,

Journal of Clinical Oncology

2010

475

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano,

Journal of Clinical Oncology

2017

345

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

S. Vincent Rajkumar, Laura Rosiñol, Mohamad A. Hussein,

Journal of Clinical Oncology

2008

343

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib,

Haematologica

2015

325

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Thierry Façon, Meletios Α. Dimopoulos, Angela Dispenzieri,

Blood

2017

267

Page 1